SI-Bone Inc (NASDAQ:SIBN) insider Scott A. Yerby sold 648 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $19.01, for a total value of $12,318.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of SIBN opened at $19.80 on Friday. The company’s 50 day simple moving average is $17.91. SI-Bone Inc has a 12-month low of $14.08 and a 12-month high of $23.03. The company has a debt-to-equity ratio of 0.47, a quick ratio of 12.70 and a current ratio of 13.06.
SI-Bone (NASDAQ:SIBN) last issued its earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.13). The company had revenue of $14.99 million during the quarter. On average, equities analysts expect that SI-Bone Inc will post -1.45 EPS for the current year.
Several research firms have recently commented on SIBN. Zacks Investment Research downgraded Yatra Online from a “hold” rating to a “sell” rating in a research note on Saturday, July 6th. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. SI-Bone presently has a consensus rating of “Buy” and an average target price of $24.75.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. Legal & General Group Plc purchased a new position in SI-Bone during the 4th quarter valued at approximately $27,000. Citigroup Inc. purchased a new position in SI-Bone during the 4th quarter valued at approximately $46,000. Valeo Financial Advisors LLC purchased a new position in SI-Bone during the 1st quarter valued at approximately $94,000. American International Group Inc. purchased a new position in SI-Bone during the 4th quarter valued at approximately $115,000. Finally, Deutsche Bank AG purchased a new position in SI-Bone during the 4th quarter valued at approximately $227,000. Institutional investors and hedge funds own 38.89% of the company’s stock.
SI-Bone Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Recommended Story: What does a bar chart display?
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.